FDMT FY 2022 Earnings — 4D Molecular Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FDMT4D Molecular Therapeutics, Inc.

$468M

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-82.7% YoY

Gross Profit

-$77M-2464.8% margin

Operating Income

-$110M-3516.5% margin

Net Income

-$107M-3435.4% margin

EPS (Diluted)

$-3.12

Cash Flow

Operating Cash Flow

-$87M

Free Cash Flow

-$98M

Stock-Based Comp.

$17M

Balance Sheet

Total Assets

$262M

Total Liabilities

$31M

Stockholders' Equity

$231M

Cash & Equivalents

$52M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$18M	-82.7%
Gross Profit	-$77M	-$43M	-78.0%
Operating Income	-$110M	-$71M	-54.3%
Net Income	-$107M	-$71M	-50.7%